{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:57Z","timestamp":1790683197303,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00134-026-08550-y","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:42:28Z","timestamp":1784108548000},"page":"2144-2159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7181","authenticated-orcid":false,"given":"Andrew J.","family":"Webb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7029","authenticated-orcid":false,"given":"Brooke","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-9969","authenticated-orcid":false,"given":"Stephanie L.","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-5839","authenticated-orcid":false,"given":"Carolina B.","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-902X","authenticated-orcid":false,"given":"Aaron M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"8550_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","volume":"62","author":"D Morales Castro","year":"2023","unstructured":"Morales Castro D, Dresser L, Granton J, Fan E (2023) Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet 62:209\u2013220. https:\/\/doi.org\/10.1007\/s40262-023-01213-x","journal-title":"Clin Pharmacokinet"},{"key":"8550_CR2","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2589-7500(23)00088-2","volume":"5","author":"H Parikh","year":"2023","unstructured":"Parikh H, Hoffman K, Sun H et al (2023) Effects of epileptiform activity on discharge outcome in critically ill patients in the USA: a retrospective cross-sectional study. Lancet Digit Health 5:e495\u2013e502. https:\/\/doi.org\/10.1016\/S2589-7500(23)00088-2","journal-title":"Lancet Digit Health"},{"key":"8550_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s12028-025-02347-5","volume":"43","author":"M Kharouba","year":"2025","unstructured":"Kharouba M, Cook AM, Bastin MLT et al (2025) Levetiracetam dosing optimization in neurocritical care population: neuro-ARC study. Neurocrit Care 43:887\u2013901. https:\/\/doi.org\/10.1007\/s12028-025-02347-5","journal-title":"Neurocrit Care"},{"key":"8550_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/FTD.0000000000000739","volume":"42","author":"ME Barra","year":"2020","unstructured":"Barra ME, Phillips KM, Chung DY, Rosenthal ES (2020) A novel correction equation avoids high-magnitude errors in interpreting therapeutic drug monitoring of phenytoin among critically ill patients. Ther Drug Monit 42:617\u2013625. https:\/\/doi.org\/10.1097\/FTD.0000000000000739","journal-title":"Ther Drug Monit"},{"key":"8550_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70079","author":"AJ Webb","year":"2025","unstructured":"Webb AJ, Brown CS, Liu J et al (2025) External validation of the Fraser equation for estimation of free valproate concentrations in critically ill adults. Pharmacotherapy n\/a: https:\/\/doi.org\/10.1002\/phar.70079","journal-title":"Pharmacotherapy n\/a:"},{"key":"8550_CR6","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1111\/epi.17304","volume":"63","author":"P Ryvlin","year":"2022","unstructured":"Ryvlin P, Dimova S, Elmoufti S et al (2022) Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials. Epilepsia 63:2024\u20132036. https:\/\/doi.org\/10.1111\/epi.17304","journal-title":"Epilepsia"},{"key":"8550_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109384","volume":"147","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Rodriguez-Osorio X, Juiz-Fern\u00e1ndez \u00c1 et al (2023) Real-life evidence about the use of intravenous brivaracetam in urgent seizures: the BRIV-IV study. Epilepsy Behav EB 147:109384. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109384","journal-title":"Epilepsy Behav EB"},{"key":"8550_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2021.100504","volume":"16","author":"L Abraira","year":"2021","unstructured":"Abraira L, Salas-Puig J, Quintana M et al (2021) Overnight switch from levetiracetam to brivaracetam. Safety and tolerability. Epilepsy Behav Rep 16:100504. https:\/\/doi.org\/10.1016\/j.ebr.2021.100504","journal-title":"Epilepsy Behav Rep"},{"key":"8550_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/jcph.82","volume":"53","author":"A Stockis","year":"2013","unstructured":"Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 53:633\u2013641. https:\/\/doi.org\/10.1002\/jcph.82","journal-title":"J Clin Pharmacol"},{"key":"8550_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","volume":"149","author":"I Aicua-Rapun","year":"2019","unstructured":"Aicua-Rapun I, Andr\u00e9 P, Rossetti AO et al (2019) Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res 149:88\u201391. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.12.001","journal-title":"Epilepsy Res"},{"key":"8550_CR11","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jcph.761","volume":"56","author":"R Schoemaker","year":"2016","unstructured":"Schoemaker R, Wade JR, Stockis A (2016) Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol 56:1591\u20131602. https:\/\/doi.org\/10.1002\/jcph.761","journal-title":"J Clin Pharmacol"},{"key":"8550_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/epi.17873","volume":"65","author":"M Hentschel","year":"2024","unstructured":"Hentschel M, Stoffel-Wagner B, Surges R et al (2024) Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy. Epilepsia 65:620\u2013629. https:\/\/doi.org\/10.1111\/epi.17873","journal-title":"Epilepsia"},{"key":"8550_CR13","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/epi.17665","volume":"64","author":"RJ Flamini","year":"2023","unstructured":"Flamini RJ, Comi AM, Bebin EM et al (2023) Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia 64:e156\u2013e163. https:\/\/doi.org\/10.1111\/epi.17665","journal-title":"Epilepsia"},{"key":"8550_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/jcpt.13082","volume":"45","author":"S Capra","year":"2020","unstructured":"Capra S, Narayan SW, Parratt K, Patanwala AE (2020) Cannabinoids for drug-resistant seizures in a critically ill patient\u2014case report and literature review. J Clin Pharm Ther 45:570\u2013572. https:\/\/doi.org\/10.1111\/jcpt.13082","journal-title":"J Clin Pharm Ther"},{"key":"8550_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/0118715273304077240603115521","volume":"24","author":"G Di Mauro","year":"2025","unstructured":"Di Mauro G, Vietri G, Quaranta L et al (2025) Effectiveness of highly purified cannabidiol in refractory and super-refractory status epilepticus: a case series. CNS Neurol Disord Drug Targets 24:158\u2013163. https:\/\/doi.org\/10.2174\/0118715273304077240603115521","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"8550_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/epi.18284","volume":"66","author":"C Johannessen Landmark","year":"2025","unstructured":"Johannessen Landmark C, S\u00e6tre J, Gott\u00e5s A et al (2025) Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy. Epilepsia 66:1477\u20131491. https:\/\/doi.org\/10.1111\/epi.18284","journal-title":"Epilepsia"},{"key":"8550_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637801","volume":"12","author":"M Contin","year":"2021","unstructured":"Contin M, Mohamed S, Santucci M et al (2021) Cannabidiol in pharmacoresistant epilepsy: clinical pharmacokinetic data from an expanded access program. Front Pharmacol 12:637801. https:\/\/doi.org\/10.3389\/fphar.2021.637801","journal-title":"Front Pharmacol"},{"key":"8550_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","volume":"95","author":"JP Szaflarski","year":"2019","unstructured":"Szaflarski JP, Hernando K, Bebin EM et al (2019) Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav 95:131\u2013136. https:\/\/doi.org\/10.1016\/j.yebeh.2019.03.042","journal-title":"Epilepsy Behav"},{"key":"8550_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1528-1157.1999.tb02074.x","volume":"40","author":"GE Mawer","year":"1999","unstructured":"Mawer GE, Jamieson V, Lucas SB, Wild JM (1999) Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy. Epilepsia 40:190\u2013196. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb02074.x","journal-title":"Epilepsia"},{"key":"8550_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1542\/peds.86.2.263","volume":"86","author":"MV Miles","year":"1990","unstructured":"Miles MV, Lawless ST, Tennison MB et al (1990) Rapid loading of critically ill patients with carbamazepine suspension. Pediatrics 86:263\u2013266","journal-title":"Pediatrics"},{"key":"8550_CR21","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/ajhp\/55.11.1134","volume":"55","author":"H Cohen","year":"1998","unstructured":"Cohen H, Howland MA, Luciano DJ et al (1998) Feasibility and pharmacokinetics of carbamazepine oral loading doses. Am J Health Syst Pharm 55:1134\u20131140. https:\/\/doi.org\/10.1093\/ajhp\/55.11.1134","journal-title":"Am J Health Syst Pharm"},{"key":"8550_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.annemergmed.2007.01.003","volume":"50","author":"TB Purcell","year":"2007","unstructured":"Purcell TB, McPheeters RA, Feil M, Chavez R (2007) Rapid oral loading of carbamazepine in the emergency department. Ann Emerg Med 50:121\u2013126. https:\/\/doi.org\/10.1016\/j.annemergmed.2007.01.003","journal-title":"Ann Emerg Med"},{"key":"8550_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1528-1157.1994.tb02932.x","volume":"35","author":"L Sch\u00e4ffler","year":"1994","unstructured":"Sch\u00e4ffler L, Bourgeois BF, L\u00fcders HO (1994) Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Epilepsia 35:195\u2013198. https:\/\/doi.org\/10.1111\/j.1528-1157.1994.tb02932.x","journal-title":"Epilepsia"},{"key":"8550_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C et al (2020) Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol 19:38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0","journal-title":"Lancet Neurol"},{"key":"8550_CR25","doi-asserted-by":"crossref","unstructured":"Kamin M, Ferrari L (2019) Time to onset of efficacy in seizure reduction with Cenobamate (YKP3089) in patients with uncontrolled partial seizures from 2 randomized clinical trials (P1.5\u2013032). Neurology 92(15_supplement):P1.5-032","DOI":"10.1212\/WNL.92.15_supplement.P1.5-032"},{"key":"8550_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/19418744221147083","volume":"13","author":"JM Carlson","year":"2023","unstructured":"Carlson JM, Molyneaux BJ, Lee JW (2023) Safe use of cenobamate in super refractory status epilepticus: a case series. The Neurohospitalist 13:169\u2013172. https:\/\/doi.org\/10.1177\/19418744221147083","journal-title":"The Neurohospitalist"},{"key":"8550_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07713-3","author":"G Falcicchio","year":"2024","unstructured":"Falcicchio G, Pellicciari R, Graziani D et al (2024) Early considerations about the safety of cenobamate in the treatment of status epilepticus. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-024-07713-3","journal-title":"Neurol Sci"},{"key":"8550_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/cpdd.769","volume":"9","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kamin M (2020) Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev 9:428\u2013443. https:\/\/doi.org\/10.1002\/cpdd.769","journal-title":"Clin Pharmacol Drug Dev"},{"key":"8550_CR29","doi-asserted-by":"crossref","unstructured":"Greene SA, Rosenfeld WE, Ferrari L (2022) Cenobamate plasma concentrations in patients reaching \u226550% or 100% responder rates for \u226512 months: a post-hoc analysis (S13.004). Neurology 98:537.","DOI":"10.1212\/WNL.98.18_supplement.537"},{"key":"8550_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/epi4.12230","volume":"3","author":"SH Mahmoud","year":"2018","unstructured":"Mahmoud SH, Rans C (2018) Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open 3:323\u2013330. https:\/\/doi.org\/10.1002\/epi4.12230","journal-title":"Epilepsia Open"},{"key":"8550_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1059-1311(98)80043-5","volume":"7","author":"C Corman","year":"1998","unstructured":"Corman C, Guberman A, Benavente O (1998) Clobazam in partial status epilepticus. Seizure 7:243\u2013247. https:\/\/doi.org\/10.1016\/S1059-1311(98)80043-5","journal-title":"Seizure"},{"key":"8550_CR32","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1111\/j.1528-1157.1986.tb05729.x","volume":"27","author":"P Tinuper","year":"1986","unstructured":"Tinuper P, Aguglia U, Gastaut H (1986) Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. Epilepsia 27:S18\u2013S26. https:\/\/doi.org\/10.1111\/j.1528-1157.1986.tb05729.x","journal-title":"Epilepsia"},{"key":"8550_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD et al (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x","journal-title":"Epilepsia"},{"key":"8550_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/19418744231189078","author":"KM Phillips","year":"2023","unstructured":"Phillips KM, Rodriguez-Lopez JM, Webb AJ (2023) Elevations in norclobazam concentrations and altered mental status in cyp2c19 poor metabolizer phenotype: a case report. The Neurohospitalist. https:\/\/doi.org\/10.1177\/19418744231189078","journal-title":"The Neurohospitalist"},{"key":"8550_CR35","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/ana.25249","volume":"83","author":"AM Husain","year":"2018","unstructured":"Husain AM, Lee JW, Kolls BJ et al (2018) Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol 83:1174\u20131185. https:\/\/doi.org\/10.1002\/ana.25249","journal-title":"Ann Neurol"},{"key":"8550_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s12028-013-9882-6","volume":"20","author":"B Legros","year":"2014","unstructured":"Legros B, Depondt C, Levy-Nogueira M et al (2014) Intravenous Lacosamide in Refractory Seizure Clusters and Status Epilepticus: Comparison of 200 and 400 mg Loading Doses. Neurocrit Care 20:484\u2013488. https:\/\/doi.org\/10.1007\/s12028-013-9882-6","journal-title":"Neurocrit Care"},{"key":"8550_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107449","volume":"114","author":"AK Chimakurthy","year":"2021","unstructured":"Chimakurthy AK, Ramsay RE, Sabharwal V, Menon U (2021) Safety, tolerability, and pharmacokinetics of weight-based IV loading dose of lacosamide in the ICU. Epilepsy Behav EB 114:107449. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107449","journal-title":"Epilepsy Behav EB"},{"key":"8550_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eplepsyres.2017.05.007","volume":"135","author":"M Perrenoud","year":"2017","unstructured":"Perrenoud M, Andr\u00e9 P, Alvarez V et al (2017) Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response. Epilepsy Res 135:38\u201342. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.05.007","journal-title":"Epilepsy Res"},{"key":"8550_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106710","volume":"176","author":"HK Kim","year":"2021","unstructured":"Kim HK, Lee H, Bae E-K, Kim DW (2021) Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy. Epilepsy Res 176:106710. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106710","journal-title":"Epilepsy Res"},{"key":"8550_CR40","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ (2018) Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 40:526\u2013548. https:\/\/doi.org\/10.1097\/FTD.0000000000000546","journal-title":"Ther Drug Monit"},{"key":"8550_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00002018-199818040-00004","volume":"18","author":"J Messenheimer","year":"1998","unstructured":"Messenheimer J, Mullens EL, Giorgi L, Young F (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18:281\u2013296. https:\/\/doi.org\/10.2165\/00002018-199818040-00004","journal-title":"Drug Saf"},{"key":"8550_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/epi4.12495","volume":"6","author":"Y Jang","year":"2021","unstructured":"Jang Y, Moon J, Kim N et al (2021) A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. Epilepsia Open 6:394\u2013401. https:\/\/doi.org\/10.1002\/epi4.12495","journal-title":"Epilepsia Open"},{"key":"8550_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bcpt.13203","volume":"125","author":"B Koristkova","year":"2019","unstructured":"Koristkova B, Grundmann M, Brozmanova H, Kacirova I (2019) Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients. Basic Clin Pharmacol Toxicol 125:26\u201333. https:\/\/doi.org\/10.1111\/bcpt.13203","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"8550_CR44","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.toxrep.2021.08.005","volume":"8","author":"KE Wood","year":"2021","unstructured":"Wood KE, Palmer KL, Krasowski MD (2021) Correlation of elevated lamotrigine and levetiracetam serum\/plasma levels with toxicity: A long-term retrospective review at an academic medical center. Toxicol Rep 8:1592\u20131598. https:\/\/doi.org\/10.1016\/j.toxrep.2021.08.005","journal-title":"Toxicol Rep"},{"key":"8550_CR45","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM et al (2019) Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 381:2103\u20132113. https:\/\/doi.org\/10.1056\/NEJMoa1905795","journal-title":"N Engl J Med"},{"key":"8550_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajem.2024.09.007","volume":"85","author":"C Schowe","year":"2024","unstructured":"Schowe C, Frick CD, Weitkamp LU, Jarboe L (2024) Evaluation of levetiracetam loading dose in adult patients with benzodiazepine-refractory status epilepticus. Am J Emerg Med 85:148\u2013152. https:\/\/doi.org\/10.1016\/j.ajem.2024.09.007","journal-title":"Am J Emerg Med"},{"key":"8550_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006065","volume":"52","author":"E Valdes","year":"2024","unstructured":"Valdes E, Fang T, Boffa M, Frontera JA (2024) Optimal dosing of levetiracetam for seizure prophylaxis in critically ill patients: a prospective observational study. Crit Care Med 52:e1. https:\/\/doi.org\/10.1097\/CCM.0000000000006065","journal-title":"Crit Care Med"},{"key":"8550_CR48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12028-022-01599-9","volume":"38","author":"K Ohman","year":"2023","unstructured":"Ohman K, Kram B, Schultheis J et al (2023) Evaluation of Levetiracetam Dosing Strategies for Seizure Prophylaxis Following Traumatic Brain Injury. Neurocrit Care 38:345\u2013355. https:\/\/doi.org\/10.1007\/s12028-022-01599-9","journal-title":"Neurocrit Care"},{"key":"8550_CR49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1528-1157.2002.33301.x","volume":"43","author":"IE Leppik","year":"2002","unstructured":"Leppik IE, Rarick JO, Walczak TS et al (2002) Effective levetiracetam doses and serum concentrations: Age effects. Epilepsia 43:240","journal-title":"Epilepsia"},{"key":"8550_CR50","doi-asserted-by":"publisher","first-page":"780","DOI":"10.5414\/CP201896","volume":"51","author":"DW Kim","year":"2013","unstructured":"Kim DW, Gu N, Lee H et al (2013) Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy. Int J Clin Pharmacol Ther 51:780\u2013786. https:\/\/doi.org\/10.5414\/CP201896","journal-title":"Int J Clin Pharmacol Ther"},{"key":"8550_CR51","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/j.1528-1167.2011.03318.x","volume":"53","author":"DW Kim","year":"2012","unstructured":"Kim DW, Gu N, Jang I-J et al (2012) Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 53:e9-12. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03318.x","journal-title":"Epilepsia"},{"key":"8550_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.seizure.2003.08.006","volume":"13","author":"F Albani","year":"2004","unstructured":"Albani F, Grassi B, Ferrara R et al (2004) Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure 13:254\u2013263. https:\/\/doi.org\/10.1016\/j.seizure.2003.08.006","journal-title":"Seizure"},{"key":"8550_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/0003088-200847120-00002","volume":"47","author":"P Bring","year":"2008","unstructured":"Bring P, Ensom MHH (2008) Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet 47:767\u2013778. https:\/\/doi.org\/10.2165\/0003088-200847120-00002","journal-title":"Clin Pharmacokinet"},{"key":"8550_CR54","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00415-021-10506-9","volume":"268","author":"S-N Lim","year":"2021","unstructured":"Lim S-N, Wu T, Tseng W-EJ et al (2021) Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review. J Neurol 268:3744\u20133757. https:\/\/doi.org\/10.1007\/s00415-021-10506-9","journal-title":"J Neurol"},{"key":"8550_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","volume":"86","author":"F Brigo","year":"2018","unstructured":"Brigo F, Lattanzi S, Rohracher A et al (2018) Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav 86:179\u2013186. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.004","journal-title":"Epilepsy Behav"},{"key":"8550_CR56","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/epi.12240","volume":"54","author":"BE Gidal","year":"2013","unstructured":"Gidal BE, Ferry J, Majid O, Hussein Z (2013) Concentration\u2013effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 54:1490\u20131497. https:\/\/doi.org\/10.1111\/epi.12240","journal-title":"Epilepsia"},{"key":"8550_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.seizure.2020.10.017","volume":"83","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Shiratani Y, Asai S et al (2020) Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. Seizure 83:181\u2013186. https:\/\/doi.org\/10.1016\/j.seizure.2020.10.017","journal-title":"Seizure"},{"key":"8550_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18517","author":"M Stoschus","year":"2025","unstructured":"Stoschus M, Schmidbauer ML, Starp J et al (2025) Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model. Epilepsia Epub: https:\/\/doi.org\/10.1111\/epi.18517","journal-title":"Epilepsia Epub:"},{"key":"8550_CR59","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/wnl.38.7.1035","volume":"38","author":"TO Crawford","year":"1988","unstructured":"Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR (1988) Very-high-dose phenobarbital for refractory status epilepticus in children. Neurology 38:1035\u20131040. https:\/\/doi.org\/10.1212\/wnl.38.7.1035","journal-title":"Neurology"},{"key":"8550_CR60","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1592\/phco.28.11.1391","volume":"28","author":"SL von Winckelmann","year":"2008","unstructured":"von Winckelmann SL, Spriet I, Willems L (2008) therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacother J Hum Pharmacol Drug Ther 28:1391\u20131400. https:\/\/doi.org\/10.1592\/phco.28.11.1391","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"8550_CR61","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1001\/archneur.1985.04060050066010","volume":"42","author":"DR Abernethy","year":"1985","unstructured":"Abernethy DR, Greenblatt DJ (1985) phenytoin disposition in obesity: determination of loading dose. Arch Neurol 42:468\u2013471. https:\/\/doi.org\/10.1001\/archneur.1985.04060050066010","journal-title":"Arch Neurol"},{"key":"8550_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.seizure.2014.09.009","volume":"24","author":"AA Asadi-Pooya","year":"2015","unstructured":"Asadi-Pooya AA, Jahromi MJ, Izadi S, Emami Y (2015) Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings. Seizure 24:114\u2013117. https:\/\/doi.org\/10.1016\/j.seizure.2014.09.009","journal-title":"Seizure"},{"key":"8550_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-025-02243-y","author":"AJ Webb","year":"2025","unstructured":"Webb AJ, Gagnon DJ, Brown CS et al (2025) Clinical consequences of disproportionate free valproate elevation in critically ill adult patients: a multicenter retrospective cohort study. Neurocrit Care. https:\/\/doi.org\/10.1007\/s12028-025-02243-y","journal-title":"Neurocrit Care"},{"key":"8550_CR64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","volume":"38","author":"CC Wu","year":"2016","unstructured":"Wu CC, Pai TY, Hsiao FY et al (2016) The effect of different carbapenem antibiotics (Ertapenem, Imipenem\/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations. Ther Drug Monit 38:587\u2013592. https:\/\/doi.org\/10.1097\/FTD.0000000000000316","journal-title":"Ther Drug Monit"},{"key":"8550_CR65","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1212\/WNL.48.1.182","volume":"48","author":"A Beydoun","year":"1997","unstructured":"Beydoun A, Sackellares JC, Shu V (1997) Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology 48:182\u2013188. https:\/\/doi.org\/10.1212\/WNL.48.1.182","journal-title":"Neurology"},{"key":"8550_CR66","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/WNL.0000000000011000","volume":"96","author":"U Fisch","year":"2021","unstructured":"Fisch U, Baumann SM, Semmlack S et al (2021) Accuracy of calculated free valproate levels in adult patients with status epilepticus. Neurology 96:e102\u2013e110. https:\/\/doi.org\/10.1212\/WNL.0000000000011000","journal-title":"Neurology"},{"key":"8550_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107139","volume":"109","author":"K Hubert","year":"2020","unstructured":"Hubert K, Knake S, Bauer S et al (2020) Treatment of status epilepticus with zonisamide: a multicenter cohort study of 34 patients and review of literature. Epilepsy Behav 109:107139. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107139","journal-title":"Epilepsy Behav"},{"key":"8550_CR68","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Wesche D, Miller R et al (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661\u2013669. https:\/\/doi.org\/10.2165\/11536200-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"8550_CR69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.ajkd.2021.06.027","volume":"79","author":"J Bouchard","year":"2022","unstructured":"Bouchard J, Yates C, Calello DP et al (2022) Extracorporeal treatment for gabapentin and pregabalin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Am J Kidney Dis Off J Natl Kidney Found 79:88\u2013104. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.027","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"8550_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-022-01459-6","author":"KM Busl","year":"2022","unstructured":"Busl KM, Fong MWK, Newcomer Z et al (2022) Pregabalin for recurrent seizures in critical illness: a promising adjunctive therapy, especially for cyclic seizures. Neurocrit Care. https:\/\/doi.org\/10.1007\/s12028-022-01459-6","journal-title":"Neurocrit Care"},{"key":"8550_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110082","volume":"160","author":"CB Maciel","year":"2024","unstructured":"Maciel CB, Ahmad B, Jose Bruzzone Giraldez M et al (2024) Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus. Epilepsy Behav 160:110082. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110082","journal-title":"Epilepsy Behav"},{"key":"8550_CR72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s1059-1311(96)80043-4","volume":"5","author":"D Bachmann","year":"1996","unstructured":"Bachmann D, Ritz R, Wad N, Haefeli WE (1996) Vigabatrin dosing during haemodialysis. Seizure 5:239\u2013242. https:\/\/doi.org\/10.1016\/s1059-1311(96)80043-4","journal-title":"Seizure"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-026-08550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-026-08550-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-026-08550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:22:48Z","timestamp":1790680968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-026-08550-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8550"],"URL":"https:\/\/doi.org\/10.1007\/s00134-026-08550-y","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJW accepts consulting fees from Grace Therapeutics. BB is currently an employee of Innoviva Specialty Therapeutics; this work was conducted separately from employment responsibilities. CBM accepts lecture honoraria from NATUS and the American Academy of Neurology for speaker engagements related to seizure disorders and therapeutic management. All authors have reviewed the manuscript and approve as submitted.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}